Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
58
datasets available to search
ShareScore release 0.9.0
Dataset results
58 results for “Cardiopulmonary exercise test;”
Cardiopulmonary Exercise Testing as an Outcome Predictor in Coronary Artery Bypass Surgery
ClinicalTrials.gov study NCT03376542. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study on the Intervention of Metabolic Syndrome Patients With Exercise Prescription Based on Ventilatory Threshold Using Cardiopulmonary Exercise Test
ClinicalTrials.gov study NCT06379204. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Cardiopulmonary Exercise Testing in Girls (8-18y) with Turner Sydrome.
ClinicalTrials.gov study NCT06780514. IPD Sharing: NO. Countries: 1. Publications: 0.
Association Between New Effort-independent Cardiopulmonary Exercise Test Variables and Postoperative Complications After Elective Colorectal Surgery
ClinicalTrials.gov study NCT05483179. IPD Sharing: NO. Countries: 1. Publications: 0.
Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation
ClinicalTrials.gov study NCT02844400. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Cardiopulmonary Exercise Testing and Oscillometry for the Evaluation of Dyspnea
ClinicalTrials.gov study NCT06554353. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
The Registry Study to Compare the Cardiopulmonary Exercise Test Parameters Before and After Cardiac Rehabilitation in Patients With Chronic Total Occlusion of the Coronary Arteries
ClinicalTrials.gov study NCT03221712. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Cardiopulmonary Exercise Testing in Cirrhotic Patients: a Pilot Study
ClinicalTrials.gov study NCT01658982. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Whole blood human transcriptome and virome analysis of ME/CFS patients experiencing post-exertional malaise following cardiopulmonary exercise testing
GEO Series GSE128078. Homo sapiens. 99 samples. Type: Expression profiling by high throughput sequencing.
The Prospects of the Two-day Cardiopulmonary Exercise Test (CPET) in ME/CFS Patients: A Meta-Analysis
<p><strong>Supplementary Tables and Figure for "The Prospects of the Two-day Cardiopulmonary Exercise Test (CPET) in ME/CFS Patients: A Meta-Analysis"</strong></p>
Comparison of E-Learning and Face-to-Face Learning in Cardiopulmonary Exercise Test Training
ClinicalTrials.gov study NCT06330285. IPD Sharing: NO. Countries: 0. Publications: 0.
Cardiopulmonary Exercise Test to Quantify Enzyme Replacement Response in Pediatric Pompe Disease
ClinicalTrials.gov study NCT03147664. IPD Sharing: NO. Countries: 0. Publications: 0.
cArdiopulmonary exerCise Test Assessing Multiple biOmarkers and Hormones iN Type 1 diabetEs Under Different Circumstances
ClinicalTrials.gov study NCT05429359. IPD Sharing: NO. Countries: 0. Publications: 0.
Cardiopulmonary Exercise Testing: An Assessment of Patients Fitness for Palliative Chemotherapy for Pancreatic Cancer
ClinicalTrials.gov study NCT03215459. IPD Sharing: NO. Countries: 0. Publications: 0.
Raw data: Role of cardiopulmonary exercise test in the prediction of hemodynamic impairment in patients with pulmonary arterial hypertension
<p>Periodic repetition of right heart catheterization (RHC) in pulmonary arterial hypertension (PAH) can be challenging. We evaluated the correlation between RHC and cardiopulmonary exercise test (CPET) aiming at CPET use as a potential noninvasive tool for hemodynamic burden evaluation. One hundred and forty‐four retrospective PAH patients who had performed CPET and RHC within 2 months were enrolled. The following analyses were performed: (a) CPET parameters in hemodynamic variables tertiles; (b) position of hemodynamic parameters in the peak end‐tidal carbon dioxide pressure (P<sub>ET</sub>CO<sub>2</sub>) versus ventilation/carbon dioxide output (VE/VCO<sub>2</sub>) slope scatterplot, which is a specific hallmark of exercise respiratory abnormalities in PAH; (c) association between CPET and a hemodynamic burden score developed including mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance (PVR), cardiac index, and right atrial pressure. VE/VCO<sub>2</sub> slope and peak P<sub>ET</sub>CO<sub>2</sub> significantly varied in mPAP and PVR tertiles, while peak oxygen uptake (peak VO<sub>2</sub>) and O<sub>2</sub> pulse varied in the tertiles of all hemodynamic parameters. P<sub>ET</sub>CO<sub>2</sub> versus VE/VCO<sub>2</sub> slope showed a strong hyperbolic relationship (<em>R</em> <sup>2</sup> =&thinsp;0.7627). Patients with peak P<sub>ET</sub>CO<sub>2</sub> > median (26 mmHg) and VE/VCO<sub>2</sub> slope < median (44) presented lower mPAP and PVR (p < 0.005) than patients with peak P<sub>ET</sub>CO<sub>2</sub> < median and VE/VCO<sub>2</sub> slope > median. Multivariate analysis individuated peak VO<sub>2</sub> (<em>p</em> =&thinsp;0.0158) and peak P<sub>ET</sub>CO<sub>2</sub> (<em>p</em> =&thinsp;0.0089) as hemodynamic score independent predictors; the formula 11.584 − 0.0925 × peak VO<sub>2</sub> − 0.0811 × peak P<sub>ET</sub>CO<sub>2</sub> best predicts the hemodynamic score value from CPET data. A significant correlation was found between estimated and calculated scores (<em>p</em> < 0.0001), with a precise match for patients with mild‐to‐moderate hemodynamic burden (76% of cases). The results of the present study suggest that CPET could allow to estimate the hemodynamic burden in PAH patients.</p> <p> </p>
RAW DATA of the paper IMPROVEMENT OF FUNCTIONAL CAPACITY IN SACUBITRIL-VALSARTAN TREATED PATIENTS ASSESSED BY CARDIOPULMONARY EXERCISE TEST
<p>Neprilisin and angiotensin receptor inhibition (Sacubitril/Valsartan, i.e. ARNI) is recommended in heart failure guidelines for patients in NYHA class II-III with reduced left ventricular ejection fraction (LVEF). ARNI increase survival and quality of life; due to their hemodynamic effects, ARNI could also affect exercise tolerance. We studied the effects of ARNI on cardiopulmonary test (CPET) after six months of treatment in 35 patients [67±11 years; LVEF 31±6%; NT-proBNP 1822±1651 pg/ml; ICD/CRT since at least 6 months in 26/35], treated with increasing doses of Sacubitril/Valsartan up to 318±36 mg/die. In addition, levels of NT-proBNP, renal function, electrolytes, and echocardiocolorDoppler were assessed in the same time periods. No variations of renal function and/or potassium levels were observed; NT-proBNP decreased. Most CPET variables were improved by ARNI (p<0.05): peak VO<sub>2</sub> and O<sub>2</sub> pulse increased (from 15.8±3.4 to 17.0±4.0 ml/Kg/min and from 11.5±2.5 to 12.6±2.4 ml/beat, respectively), while VEVCO<sub>2</sub> slope decreased from 35.2±11.2 to 33.1±12.3. A significant relationship (p<0.05) was observed between the amount of increase in LVEF and that of O<sub>2</sub> pulse in all patients, and between the amount of decrease in PAPs and that of VEVCO<sub>2</sub> slope in patients showing pulmonary hypertension in baseline. In a subgroup of 22 patients who already completed A 1 year follow-up, overall CPET improvement was maintained. In conclusion, already in the short term ARNI favorably affect cardiopulmonary response to exercise in heart failure patients; such a change seems to be preserved on a longer period.</p>
Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test.
<p>Raw data of the paper: </p> <p>Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test.</p> <p> </p> <p>Background</p> <p>Heart failure with midrange ejection fraction (HFmrEF) represents a heterogeneous category where phenotype, as well as prognostic assessment, remains debated. The present study explores a specific HFmrEF subset, namely those who recovered from a reduced EF (rec-HFmrEF) and, particularly, it focuses on the possible additive prognostic role of cardiopulmonary exercise testing.</p> <p>Methods and Results</p> <p>We analyzed data from 4535 patients with HFrEF and 1176 patients with rec-HFmrEF from the Metabolic Exercise combined with Cardiac and Kidney Indexes database. The end point was cardiovascular death at 5 years. The median follow-up was 1343 days (25th–75th range 627–2403 days). Cardiovascular death occurred in 552 HFrEF and 61 rec-HFmrEF patients. The multivariate analysis confirmed an independent role of the MECKI score's variables in HFrEF (C-index = 0.744) whereas, in the rec-HFmrEF group, only age and peak oxygen uptake (pVO<sub>2</sub>) remained associated to the end point (C-index = 0.745). A peak oxygen uptake of ≤55% of predicted and a ventilatory efficiency of ≥31 resulted as the most accurate cut-off values in the outcome prediction.</p> <p>Conclusions:</p> <p>Present data support the cardiopulmonary exercise test and, particularly, the peak oxygen uptake, as a useful tool in the rec-HFmrEF prognostic assessment. A peak VO<sub>2</sub> of ≤55% predicted and ventilatory efficiency of ≥31 might help to identify a high-risk rec-HFmrEF subgroup.</p> <ul> </ul>
Dataset related to the publication "Brisk walking can be a maximal effort in heart failure patients: a comparison of cardiopulmonary exercise and 6 min walking test cardiorespiratory data"
<p><strong>Aims: </strong>Cardiopulmonary exercise test (CPET) and 6 min walking test (6MWT) are frequently used in heart failure (HF). CPET is a maximal exercise, whereas 6MWT is a self-selected constant load test usually considered a submaximal, and therefore safer, exercise, but this has not been tested previously. The aim of this study was to compare the cardiorespiratory parameters collected during CPET and 6MWT in a large group of healthy subjects and patients with HF of different severity.</p> <p><strong>Methods and results: </strong>Subjects performed a standard maximal CPET and a 6MWT wearing a portable device allowing breath-by-breath measurement of cardiorespiratory parameters. HF patients were grouped according to their CPET peak oxygen uptake (peakV̇O<sub>2</sub> ). One hundred and fifty-five subjects were enrolled, of whom 40 were healthy (59 ± 8 years; male 67%) and 115 were HF patients (69 ± 10 years; male 80%; left ventricular ejection fraction 34.6 ± 12.0%). CPET peakV̇O<sub>2</sub> was 13.5 ± 3.5 mL/kg/min in HF patients and 28.1 ± 7.4 mL/kg/min in healthy subjects (P < 0.001). 6MWT-V̇O<sub>2</sub> was 98 ± 20% of the CPET peakV̇O<sub>2</sub> values in HF patients, while 72 ± 20% in healthy subjects (P < 0.001). 6MWT-V̇O<sub>2</sub> was >110% of CPET peakV̇O<sub>2</sub> in 42% of more severe HF patients (peakV̇O<sub>2</sub> < 12 mL/kg/min). Similar results have been found for ventilation and heart rate. Of note, the slope of the relationship between V̇O<sub>2</sub> at 6MWT, reported as a percentage of CPET peakV̇O<sub>2</sub> vs. 6MWT V̇O<sub>2</sub> reported as the absolute value, progressively increased as exercise limitation did.</p> <p><strong>Conclusions: </strong>In conclusion, the last minute of 6MWT must be perceived as a maximal or even supramaximal exercise activity in patients with more severe HF. Our findings should influence the safety procedures needed for the 6MWT in HF.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.